Taken together, these results raise a concern about targeted inactivation of Vegfa in RPE cells using AAV and suggest that Hif1a could be inactivated without causing cone dysfunction to avoid neovascularization for the treatment of AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.